Chaojin Hong
Hangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Synergistic Anticancer Effects of COL6A1 Downregulation and the PD1 Inhibitor Pembrolizumab in Bladder Cancer.
Journal: Journal of biochemical and molecular toxicology
Published: February 06, 2025
Downregulated CDK10 promotes cancer progression and radioresistance in lung cancer through activating the JNK/c-Jun signaling pathway.
Journal: BMB reports
Published: March 02, 2024
Aumolertinib in NSCLC with leptomeningeal involvement, harbouring concurrent EGFR exon 19 deletion and TP53 comutation: a case report.
Journal: Journal of thoracic disease
Published: May 25, 2023
Roles of USP9X in cellular functions and tumorigenesis (Review).
Journal: Oncology letters
Published: April 03, 2023
Knockdown of lncRNA PCAT6 suppresses the growth of non-small cell lung cancer cells by inhibiting macrophages M2 polarization via miR-326/KLF1 axis.
Journal: Bioengineered
Published: May 24, 2022
Demethoxycurcumin increases the sensitivity of cisplatin-resistant non-small lung cancer cells to cisplatin and induces apoptosis by activating the caspase signaling pathway.
Journal: Oncology letters
Published: February 01, 2020
CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study.
Journal: Medicine
Published: December 30, 2016
Showing 1-9 of 9
Last Updated: 09/26/2026